Min Cui
Founder and Managing Director @ Decheng Capital
San Francisco, United States
Min Cui is a Series B investor at Decheng Capital in San Francisco focused on Biotechnology and Health Care. Min Cui is based out of Menlo Park, California and is the Founder and Managing Director of Decheng Capital. Min previously worked at Bay City Capital as an Investment Partner. Min Cui attended the Stanford University School of Medicine.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 83%
Last updated:
For AI agents: llms.txt
Industries Min Cui invests in
Stages Min Cui invests in
Countries Min Cui invests in
Investment Focus
Industry
- Biotechnology 8 (67%)
- Health Care 4 (33%)
- Health Diagnostics 3 (25%)
- Therapeutics 2 (17%)
- Medical Device 2 (17%)
Stage
- Series B 6 (50%)
- Series A 2 (17%)
- Series C 2 (17%)
- Venture - Series Unknown 1 (8%)
Country
- United States 8 (67%)
- China 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Polares Medical
|
Polares medical is a medical device company with a novel device for treating mitral valve regurgitation. | $50M / Series C / Mar 03, 2026 | |
VintaBio
|
VintaBio offers cell and gene therapy manufacturing services to pharmaceutical and biotechnology organizations. VintaBio is a life sciences business with unparalleled industry knowledge that is assisting in the alleviation of the viral vector bottleneck in cell and gene therapy development. | $64M / Venture - Series Unknown / Apr 11, 2023 | |
Mirvie
|
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States. | $45M / Series B / May 17, 2022 | |
ImmPACT Bio
|
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. | $139.9M / Series B / Jan 20, 2022 | |
Shape Therapeutics
|
Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA Gene Therapy, potentially enabling the development of cures in neurodegenerative, metabolic and rare genetic diseases through our breakthrough payload, delivery, and manufacturing platform technologies. Our vision is to facilitate adoption of thesetechnologies throughout the industry to develop effective treatments for as many patients as possible. | $112M / Series B / Jul 15, 2021 | |
|
Shape Therapeutics
|
Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA Gene Therapy, potentially enabling the development of cures in neurodegenerative, metabolic and rare genetic diseases through our breakthrough payload, delivery, and manufacturing platform technologies. Our vision is to facilitate adoption of thesetechnologies throughout the industry to develop effective treatments for as many patients as possible. | $112M / Series B / Jul 15, 2021 | |
Bioheng
|
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation andclinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients. | $79.7M / Series B / Mar 24, 2021 | |
LevitasBio
|
Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Their disruptive technology overcomes the current technological limitation of cellular analysis by providing label-free, simple, and universal methods of analysis. The company's platform, the LeviCell enables studies and beneficial uses ofpreviously inaccessible, high-value primary samples, and sensitive cell types regardless of the starting cell number, viability, or sensitivity to processing. | $18M / Series B / Jan 05, 2021 | |
ARMO BioSciences
|
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California. | $67M / Series C / Aug 29, 2017 | |
GeneWEAVE
|
GeneWeave Biosciences is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections.The company’s innovative and proprietarySmarticles™ technology harnesses the power of biology to enable homogeneous assays that rapidly measure bacterial drug resistance without the need for enrichment, culture, or sample preparation. | $12M / Series B / Jun 20, 2014 | |
| See all 12 investments → | |||
Co-Investors
Foresite Capital
3 deals together
Mission BioCapital
2 deals together
Breton Capital Management
2 deals together
Claremont Creek Ventures
2 deals together
venBio Partners
2 deals together
Willett Advisors LLC
2 deals together
About Decheng Capital
Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successfulcompanies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.
Decheng Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dan Zabrowski
Venture Partner
|
|||
|
Min Cui
Founder and Managing Director
|
|||
Dayton Misfeldt
Partner
|
|||
Nathan Pliam
Partner
|
|||
Victor Tong
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Min Cui invest in?
Min Cui invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Min Cui last invest?
The most recent investment recorded for Min Cui closed in Mar 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
